Related Experiment Videos
[Effects of mitomycin C perfusion after bladder tumor surgery]
Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery]
|November 1, 1989
Summary
Mitomycin C perfusion after surgery effectively prevents bladder tumor recurrence in T1-T2 stage patients. Long-term follow-up showed zero recurrence in treated cases, unlike the control group.
Area of Science:
- Oncology
- Urology
- Pharmacology
Context:
- Bladder tumors, particularly T1-T2 stage, have a risk of post-operative recurrence.
- Preventative strategies are crucial for improving patient outcomes and reducing healthcare burdens.
Purpose:
- To evaluate the efficacy of Mitomycin C perfusion in preventing bladder tumor recurrence after surgical resection.
- To assess the long-term outcomes of Mitomycin C perfusion in patients with T1-T2 stage bladder cancer.
Summary:
- A study involving 26 patients with T1-T2 stage bladder tumors investigated the use of Mitomycin C perfusion post-surgery.
- Over a follow-up period of one to eight years, none of the 26 patients receiving Mitomycin C perfusion experienced tumor recurrence.
- In contrast, 14 out of 64 patients in the control group (without Mitomycin C perfusion) experienced recurrence.
Impact:
- Mitomycin C perfusion demonstrates significant potential as an effective method for preventing bladder tumor recurrence.
- This approach may offer a valuable strategy to improve long-term disease control in non-muscle invasive bladder cancer.
- Further discussion includes the methods and potential adverse effects associated with Mitomycin C perfusion therapy.